Company looks to validate first of its kind LDTs intended for immediate clinical use and drive rapidly expanding partnership projects. SOUTH SAN FRANCISCO, Calif.–InterVenn Biosciences today announced it has raised $34M in a Series B fundraising. The latest round was led by Anzu Partners with full participation of Genoa Ventures, […]

Happy Malaysia Day (16th September 2019) to all Malaysians! On behalf of InterVenn Biosciences (InterVenn), I wish all Malaysians unity, prosperity, and importantly, happiness and good health! On this auspicious day, I would like to take some time to reflect on InterVenn’s efforts and contributions to women’s healthcare in Malaysia, […]

It’s the late 2010’s, and genomic technologies have matured. The knowledge gleaned from yesterday’s basic research is beginning to make inroads into clinical practice, so it’s natural to seek out new frontiers. The central dogma of biology dictates that DNA stores our genetic information, RNA transcribes it for translation into […]

Our body is made up of proteins. Measuring the abundances of these proteins has been the primary goal of scientists because they give us a way of understanding diseases. More careful analysis of proteins reveals that no matter how similar proteins seem, they are not really the same. Proteins become […]

We envision a time when cancer is no longer a problem – and all disease a mere nuisance. We envision a place where previously unrelated disciplines are un-siloed and interact together in unison to pursue a solution. Here, maladies are holistically understood, adequately controlled and even manipulated to benefit all. […]

Most proteomic endeavors have focused on identifying and quantifying expression levels of low abundance proteins. These queries are necessary but not sufficient, as the assessment of proteins is incomplete without simultaneously shining light on post-translational modifications (PTMs) and how they augment the proteome. PTMs decorate translated proteins in a dynamic […]

Funding to accelerate InterVenn’s development of its AI-driven mass spectrometry platform that measures glycoproteomic markers that have been strongly linked to tumor development and progression. Redwood City, Calif, December 12, 2018: — InterVenn BioSciences, a life sciences and technology company developing an AI-driven mass spectrometry platform, announced today an institutional […]